What Researchers Did
Researchers conducted a prospective, patient-blind controlled pilot trial involving four subjects with vascular subcortical frontal syndrome (VSFS) and leukoaraiosis (LA) to evaluate the efficacy and safety of hyperbaric oxygen therapy (HBO) compared to hyperbaric air.
What They Found
All four subjects experienced noticeable improvements in gait, urinary function, and cognition after hyperbaric oxygen therapy (HBO), increasing their independence. These improvements lasted for four to five months before deficits reappeared. When three patients received hyperbaric air (controls), their condition did not improve, while the one patient who received a second HBO regimen improved again.
What This Means for Canadian Patients
For Canadian patients with vascular subcortical frontal syndrome and leukoaraiosis, this preliminary study suggests that hyperbaric oxygen therapy might offer temporary improvements in symptoms like gait, urinary function, and cognition. However, these benefits appear to be short-lived, and more extensive research is needed to confirm these findings and establish long-term efficacy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The primary limitation of this study is its very small sample size of only four subjects, making the findings highly preliminary and not generalizable.